Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.
AuteursVan Baelen K, Nguyen HL, Richard F, Zels G, Karsten MM, Nader-Marta G, Vermeulen P, Dirix L, Dordevic AD, de Azambuja E, Larsimont D, Maetens M, Biganzoli E, Wildiers H, Smeets A, Nevelsteen I, Neven P, Floris G, Desmedt C
Comprehensive profiling of the mutational landscape of hidradenoma papilliferum validates key role of alterations in the PI3K/AKT pathway.
AuteursCheema S, van der Weyden L, Wong K, Del Castillo Velasco-Herrera M, Billington J, Vermes I, Anderson E, Allen L, de Saint Aubain N, van der Horst MPJ, Alomari AK, Mogler C, Monteagudo C, Frew D, Billings SD, Arends MJ, Ferreira I, Brenn T, Adams DJ
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.
AuteursBardia A, Rugo HS, Sedrak MS, Loibl S, Tolaney SM, Punie K, Hurvitz SA, Kalinsky KM, Cortés J, O'Shaughnessy JA, Dieras V, Piccart-Gebhart MJ, Dasgupta A, Kaushik A, Lai C, Shi L, Brufsky A